Ferumoxytol, a novel, semi-synthetic, superparamagnetic iron oxide nanoparticle administered by injection, is well tolerated and has a safety profile similar to placebo in CKD patients with anemia, according to a report in the American Journal of Kidney Diseases (2008;52:907-915).

That conclusion is based on a phase 3 crossover study of 750 CKD patients, 60% of whom were not on dialysis. The study compared ferumoxytol with saline (placebo).

Serious adverse events occurred in 2.9% of patients after ferumoxytol treatment and 1.8% of patients following placebo administration.

Continue Reading